Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Genie29jon Oct 15, 2023 5:33pm
127 Views
Post# 35684536

Is this the week?

Is this the week?

Alright ladies and gentlemen...this should be THE week!!! 

let's hope by tge end of the week we all have reason to seriously celebrate. 

If Replicel wins, I think it'll be important for Andrew and team to line up incremental investments to start moving the product into the marketplace. We need RCH in the hands (er, scalps) of customers ASAP to start collecting revenue. I think if they win, and the results are decent, getting investors / investments should happen relatively quickly. I wouldn't be terribly surprised if they delute the stock even future to also do so depending on how agreesive Andrew is. While dilution may be necessary, and if so, let's hope it's not too much. 

In theory, this could move 1,500-3,500% this week, if there is a positive ruling. $1.25-$2.50 price tag. 


JC

<< Previous
Bullboard Posts
Next >>